<DOC>
	<DOCNO>NCT02123654</DOCNO>
	<brief_summary>The purpose study demonstrate proportion treatment-naive non-cirrhotic subject Genotype ( GT ) -1b treat Daclatasvir ( DCV ) /Asunaprevir ( ASV ) /BMS-791325 achieve Sustained Virologic response ( SVR12 ) , define Hepatitis C virus ( HCV ) RNA &lt; LOQ target detect target detect ( LOQ TD/TND ) follow-up Week 12 , significantly high SVR12 current Standard Care ( SOC ) .</brief_summary>
	<brief_title>UNITY 3 : A Japanese Phase 3 Study Daclatasvir/Asunaprevir/BMS-791325 Subjects With Genotype 1 Chronic Hepatitis C</brief_title>
	<detailed_description>Limit Quantitation ( LOQ ) Ribonucleic acid ( RNA ) End Treatment ( EOT ) Triple Direct Acting Antivirals ( 3DAA )</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Males female , ≥ 20 year age Subjects chronically infect HCV GT1 HCV RNA viral load ≥ 100,000 IU/mL Hepatocellular carcinoma Coinfection Hepatitis B virus ( HBV ) Human immunodeficiency virus ( HIV ) Severe uncontrollable complication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>